GlassScriptPhysician profile
Briana Luxem
NPI 1396578183
$940.88
in general payments reported to CMS, 2019-2025
20 companies · $669 in 2025
The $669 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $272 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $111.32 | 2024-2025 | |
| Novo Nordisk INC | $98.09 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $79.89 | 2025 | Mounjaro, Jardiance |
| Abbvie INC. | $78.09 | 2025 | |
| Exact Sciences Corporation | $74.79 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $73.99 | 2024-2025 | Farxiga |
| Shield Therapeutics INC | $67.15 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.35 | 2025 | Caplyta |
| Astellas Pharma US INC | $47.73 | 2025 | Veozah |
| Pfizer INC. | $41.65 | 2025 | |
| Glaxosmithkline, LLC. | $38.20 | 2024-2025 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $31.64 | 2025 | Nexletol |
| Lundbeck LLC | $24.26 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.13 | 2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $22.70 | 2024 | Givlaari |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $19.90 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Hikma Pharmaceuticals USA | $15.72 | 2025 | Ryaltris |
| Axsome Therapeutics, INC. | $15.70 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $14.71 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.87 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Briana Luxem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.